The role of inflammatory mediators in the biology of major depression: Central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection

Molecular Psychiatry

Volumn 4, Issue 4, 1999, Pages 317-327

  Licinio, J ^a   Wong, M L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cytokines; Depression; Interleukins; Neuroprotection; Neurotoxicity

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

APOPTOSIS; BEHAVIOR; BONE MINERAL; BRAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DEPRESSION; HUMAN; INFECTION; INFLAMMATION; ISCHEMIA; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NECROSIS; NEOPLASM; NEUROPROTECTION; NEUROTOXICITY; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STRESS;

EID: 0032821630     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000586     Document Type: Review

References (92)

1. Raju TN. The Nobel chronicles. 1927: Julius Wagner-Jauregg (1857-1940). Lancet 1998; 352: 1714.
2. Prolo P, Licinio J. Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999; 4: 109-111.
3. Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease, 5th edn. WB Saunders: Philadelphia, 1999.
4. Maes M, Bosmans E, Meltzer HY, Scharpe S, Say E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-1193.
5. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161-167.
6. Maes M, Bosmans E, De JR, Kenis G, Vandoolaeghe E, Neels H. Incrased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment, resistant depression. Cytokine 1997; 9; 853-858.
7. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62: 583-606.
8. March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641-647.
9. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC et al. Cloning and expression of murine interleukin-1 cDNA in Eschericia coli. Nature 1984; 312: 458-462.
10. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-340.
11. Eisenberg SP, Evans RJ, Areud WP, Verderber E, Brewer MT, Hannum CH et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-346.
12. Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241: 585-589.
13. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. Embo J 1991; 10: 2821-2832.
14. Liu C, Chalmers D, Maki R, De SE. Rat homolog of mouse interleukin-1 receptor accessory protein: cloning, localization and modulation studies. J Neuroimmunol 1996; 66: 41-48.
15. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991; 174: 1251-1254.
16. Lovenberg TW, Crowe PD, Liu C, Chalmers DT, Liu XJ, Liaw C et al. Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J Neuroimmunol 1996; 70: 113-122.
17. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 1996; 271: 3967-3970.
18. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
19. Colotta F, Re F, Muzio M, Polentarutti N, Minty A, Caput D el al. Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 1994; 269: 12403-12406.
20. Licinio J, Wong M-L. Pathways and mechanisms for cytokine signalling of the central nervous system. J Clin Invest 1997; 100: 2941-2947.
21. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat, Neuroscience 1998; 84: 923-933.
22. Weiss JM, Sundar SK, Becker KJ, Cierpial MA. Behavioral and neural influences on cellular immune responses: effects of stress and interleukin-1. J Clin Pyschiatry 1989; 50 (Suppl): 43-53.
23. Bluthe RM, Sparber S, Dantzer R. Modulation of the behavioural effects of interleukin-1 in mice by nitric oxide. Neuroreport 1992; 3: 207-209.
24. Bluthe RM, Danzter R, Kelley KW. Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor alpha in mice. Eur J Pharmacol 1991; 209: 281-283.
25. Bluthe RM, Crestani F, Kelley KW, Dantzer R. Mechanisms of the behavioral effects of interleukin 1. Role of prostaglandins and CRF. Ann N Y Acad Sci 1992; 650: 268-275.
26. Bluthe RM, Michaud B, Kelley KW, Dantzer R. Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. Neuroreport 1996; 7: 1485-1488.
27. Bluthe RM, Beaudu C, Kelley KW, Dantzer R. Differential effects of IL-1ra on sickness behaviour and weight loss induced by IL-1 in rats. Brain Res 1995; 677: 171-176.
28. Linthorst AC, Flachskamm C, Muller PP, Holsboer F, Reul JM. Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels, an in vivo microdialysis study. J Neurosci 1995; 15: 2920-2934.
29. Berkenbosch F, van Oers J, del Rey A, Tilders F, Basedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin 1. Science 1987; 238: 524-526.
30. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin releasing factor. Science 1987; 238: 522-524.
31. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995; 216: 560-567.
32. Prolo P, Wong ML, Licinio J. Leptin. Int J Biochem Cell Biol 1998; 30: 1285-1290.
33. Licinio J, Flier JS, Gold PW, Wang M-L, inventors; Beth Israel Deaconess Hospital-National Institutes of Health, assignee. Methods of neuroendocrine regulation of affective disorders. USA patent 5 866 547. 2/2/1999.
34. Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci USA 1999; 96: 7047-7052.
35. Quagliarello VJ, Wispelwey B, Long WJ, Scheld WM. Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J Clin Invest 1991; 87: 1360-1366.
36. Sippy BD, Hofman FM, Wallach D, Hinton DR. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10: 511-521.
37. Weiss JM, Sundar SK. Interleukin-1: effects in the central nervous system and relevance to AIDS. Clin Neuropharmacol 1992; 66: 1A-2A.
38. Gagliardini V, Fernandez PA, Lee RK, Drexler HC, Rotello RJ, Fishman MC et al. Prevention of vertebrate neuronal death by the crmA gene. Science 1994; 263: 826-828.
39. Bauer J, Strauss S, Schreiter GU, Ganter U, Schlegel P, Witt I et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. Febs Lett 1991; 285: 111-114.
40. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system, I: Expression and recognition. Trends Neurosci 1995; 18: 83-88.
41. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neural 1991; 30: 694-700.
42. Wong ML, Loddick SA, Bongiorno PB, Gold PW, Rothwell NJ, Licinio J. Focal cerebral ischemia induces CRH mRNA in rat cerebral cortex and amygdala. Neuroreport 1995; 6: 1785-1788.
43. Loddick SA, Wang ML, Bangiorno PB, Gold PW, Licinio J, Rothwell NJ. Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem Biophys Res Common 1997; 234: 211-215.
44. Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240: 321-324.
45. Cunningham ETJ, Wada E, Carter DB, Tracey DE, Battey JF, De Souza EB. In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J Neurosci 1992; 12: 1101-1114.
46. Licinio J, Wong ML, Gold PW. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991; 129: 562-564.
47. Gabellec MM, Griffais R, Fillion G, Haour F. Expression of interleukin 1 alpha, interleukin 1 beta and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain Res Mol Brain Res 1995; 31: 122-130.
48. Ericsson A, Liu C, Hart RP, Sawchenko PE. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 1995; 361: 681-698.
49. Yabuuchi K, Minami M, Katsumata S, Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Brain Res Mol Brain Res 1994; 27: 27-36.
50. Wong M-L, Licinio J. Localization of interleukin 1 type 1 receptor mRNA in rat brain. Neuroimmunomodulation 1994; 1: 110-115.
51. Wong M-L, Bongiorno PB, Gold PW, Licinio J. Localization of interluekin-1 beta converting enzyme mRNA in rat brain vasculature: evidence that the genes encoding the interleukin-1 system are constitutively expressed in brain blood vessels. Pathophysiological implications. Neuroimmunomodulation 1995; 2: 141-148.
52. Wong M-L, Bongiorno PB, Al-Shekhlee A, Esposito A, Khatri P, Licinio J. IL-1β, IL-1 receptor type I, and iNOS gene expression in rat brain vasculature and perivascular areas. NeuroReport 1996; 7: 2445-2448.
53. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29: 243-246.
54. Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X et al. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke 1998; 29: 1937-1950.
55. Yang GY, Liu XH, Kadoya C, Zhao YJ, Mao Y, Davidson BL et al. Attenuation of ischemic inflammatory response in mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. J Cereb Blood Flow Metab 1998; 18: 840-847.
56. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913.
57. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 2023-2028.
58. Lyons MK, Anderson RE, Meyer FB. Corticotropin-releasing factor antagonist reduces ischemic hippocampal neuronal injury. Brain Res 1991; 545: 339-342.
59. Strijbos PJ, Relton JK, Rothwell NJ. Corticotrophin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain. Brain Res 1994; 656: 405-408.
60. Nemeroff CB, Wilderlov E, Bisette G, Walleus H, Karlsson I, Edlund K et al. Elevated concentrations of CSF corticotrophin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226: 1342-1344.
61. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH et al. Responses to corticotropin-releasing hormone in the hyper-cortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314: 1329-1335.
62. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psych 1988; 45: 577-579.
63. Gold PW, Gwirtsman H, Averginos PC, Nieman LK, Gallucci WT, Kaye W et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Mod 1986; 314: 1335-1342.
64. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Reciprocal changes in corticotropin-releasing-factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 1986; 319: 593-595.
65. Sheline YI. Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity. Mol Psychiatry 1996; 1: 298-299.
66. Kakucska I, Qi Y, Clark BD, Lechan RM. Endotoxin-induced corticotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is mediated centrally by interleukin-1. Endocrinology 1993; 133: 815-821.
67. Wong M-L, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997; 94: 227-232.
68. Quan N, Sundar SK, Weiss JM. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J Neuroimmunol 1994; 49: 125-134.
69. Weiss JM, Quan N, Sundar SK. Widespread activation and consequences of interleukin-1 in the brain. Ann N Y Acad Sci 1994; 741: 338-357.
70. Romero LI, Tatro JB, Field JA, Reichlin S, Roles of IL-1 and TNF-alpha in endotoxin-induced activation of nitric oxide synthase in cultured rat brain cells. Am J Physiol 1996; 270: R326-332.
71. Wong M-L, Rettori V, Al-Shekhlee A, Bongiorno PB, Canteros G, McCann SM et al. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nature Med 1996; 2: 581-584.
72. Licinio J, Prolo P, McCann SM, Wong ML. Brain iNOS: current understanding and clinical implications. Mol Med Today 1999; 5: 225-232.
73. McCann SM, Licinio J, Wang ML, Yu WH, Karanth S, Ruttorri V. The nitric oxide hypothesis of aging. Exp Gerontol 1998; 33: 813-826.
74. Scammell TE, Griffin JD, Elmquist JK, Saper CB. Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. Am J Physiol 1998; 274: R783-789.
75. Scammell TE, Elmquist JK, Saper CB. Inhibition of nitric oxide synthase produces hypothermia and depresses lipopolysaccharide fever. Am J Physiol 1996; 271: R333-338.
76. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 1987; 238: 519-521.
77. Laye S, Parnet P, Goujon E, Danlzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res Mol Brain Res 1994; 27: 157-162.
78. Romero LI, Kakucska I, Lechan RM, Reichlin S. Interleukin-6 (IL-6) is secreted from the brain after intracerebroventricular injection of IL-1 beta in rats. Am J Physiol 1996; 270: R518-R524.
79. Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M. Immobilization stress induces interleukin 1-β mRNA in the rat hypothalamus. Neurosci Lett 1991; 123: 254-256.
80. Takao T, Tojo C, Nishioka T, Makino S, Hashimoto K, De SE. Stress-induced upregulation of pituitary interleukin-1 receptors is mediated by corticotropin releasing factor. Life Sci 1996; 56: PL165-168.
81. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P et al. Psychiatric implications of basic and clinical studies with corlicotropin-releasing factor. Am J Psychiatry 1984; 141: 619-627.
82. Gold PW, Wong ML, Chrousos GP, Licinio J. Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Mol Psychiatry 1996; 1: 257-264.
83. Hosboer F, Girken A, Stalia GK, Muller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression, New Engl J Med 1984; 311: 1127.
84. Michelson D, Stratakis S, Hill L, Reynolds J, Galliyen BS, Chrousos GP et al. Bone mineral density in women with depression. N Engl J Med 1996; 335: 1176-1181.
85. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4-11.
86. Nguyen, KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, Maier SF. Exposure to acute stress induces brain interleukin-beta protein in the rat. J Neurosci 1988; 18: 2239-2246.
87. Suzuki E, Shintani F, Kanba S, Asai M, Nakaki T. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci Lett 1996; 215: 201-204.
88. Brady, LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M. Longterm antidepressant administration alters corticotropon-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991; 87: 831-837.
89. Rothwell NJ, Luheshi G, Toulmond S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 1996; 69: 85-95.
90. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuilous or causative association. Mol Psychiatry 1999; 4: 328-332.
91. Plata-Salamán C, Turrin NP. Cytokine interactions and cytokine balance in the brain: relevance to neurology and psychiatry. Mol Psychiatry 1999; 4: 303-306.
92. Plata-Salamán C, Turrin NP. Cytokine action in the brain. Mol Psychiatry 1999; 4: 302.